Search results for " disorder"

showing 10 items of 6182 documents

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct

The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, …

2018

The re-emergence (i.e. ‘breakthrough’) of depressive symptoms despite maintenance treatment of depression with antidepressant drugs is a complex clinical phenomenon referred to as tolerance. Herein we critically appraise evidence from both pre-clinical and clinical studies, focusing on putative mechanisms as well as clinical correlates and implications of the emergence tolerance during antidepressant treatment for major depressive disorder (MDD). It is firstly unclear to what extent this phenotype reflects a pharmacological effect of an antidepressant, is driven by non-adherence, is a marker of latent bipolarity or another comorbidity, a marker of neuroprogression of the underlying disorder…

0301 basic medicineEmotional bluntingLoss of efficacyAntidepressantTreatment-resistanceSerotonergicloss of response03 medical and health sciences0302 clinical medicinetachyphylaxisMedicineRelapseswitch.Depression (differential diagnoses)treatment-resistancerelapsePharmacologyantidepressantwithdrawalbusiness.industryOperational definitionSwitchloss of efficacymedicine.diseaseComorbidity030104 developmental biologyWithdrawal030220 oncology & carcinogenesisMajor depressive disorderAntidepressantLoss of responsebusinessTachyphylaxiTolerancePsychosocialClinical psychologyPharmacological Research
researchProduct

Intrasinusoidal HHV8-EBV–Positive Large B-Cell Lymphoma With Features of Germinotropic Lymphoproliferative Disorder

2020

Germinotropic lymphoproliferative disorder (GLPD) is a poorly characterized lymphoproliferative entity, recently included in the World Health Organization classification of hematolymphoid neoplasms. The histological pattern of this disease comprises monotypic plasmablasts that involve the germinal centers of the lymphoid follicles (germinotrophism), forming confluent aggregates positive for both human herpes virus type 8 (HHV8) and Epstein-Barr virus. Currently, after 17 years of its first description, only 18 cases have been reported. In this article, we describe a case of a GLPD presenting in an immunocompetent 79-year-old woman with localized axillary lymphadenopathy, showing a prominen…

0301 basic medicineEpstein-Barr Virus InfectionsHerpesvirus 4 HumanPathologymedicine.medical_specialtyLymphoma B-Cellmedicine.disease_causePathology and Forensic Medicine03 medical and health sciences0302 clinical medicinemedicineAxillary LymphadenopathyHumansB-cell lymphomaAnaplastic large-cell lymphomaAgedbusiness.industryGerminal centerHerpesviridae Infectionsmedicine.diseaseEpstein–Barr virusLymphoproliferative DisordersLymphoma030104 developmental biologyPleomorphism (cytology)030220 oncology & carcinogenesisHerpesvirus 8 HumanFemaleSurgeryLymph NodesAnatomyDifferential diagnosisbusinessInternational Journal of Surgical Pathology
researchProduct

Protective and regenerative effects of a novel medical device against esophageal mucosal damage using in vitro and ex vivo models.

2020

Gastroesophageal reflux disease (GERD) is a common digestive disorder that causes esophagitis and injuries to the esophageal mucosa. GERD symptoms are recurrent during pregnancy and their treatment is focused on lifestyle changes and nonprescription medicines. The aim of this study was to characterize the mechanism of action of a new patented medical device, an oral formulation containing hyaluronic acid, rice extract, and amino acids dispersed in a bioadhesive polymer matrix, by assessing its protective effects in in vitro and ex vivo models of esophageal mucosa damage. Acidic bile salts and pepsin cocktail (BSC) added to CP-A and COLO-680 N esophagus cells were used as an in vitro GERD mo…

0301 basic medicineEsophageal MucosaHyaluronic acidRM1-950PharmacologyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePepsinCell Line TumorDigestive disorderHyaluronic acidMedicineHumansRegenerationEsophagusAmino AcidsHyaluronic AcidEvans BlueMedical devicePharmacologybiologybusiness.industryBioadhesive polymer; Gastroesophageal reflux disease (GERD); Hyaluronic acid; Medical device; Rice extractPlant ExtractsRice extractAdhesivenessOryzaGeneral MedicineBioadhesive polymermedicine.diseaseGastroesophageal reflux disease (GERD)digestive system diseases030104 developmental biologymedicine.anatomical_structurechemistryEquipment and Supplies030220 oncology & carcinogenesisbiology.proteinGERDGastroesophageal RefluxTherapeutics. PharmacologybusinessWound healingEx vivoBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

A TRAPPC6B splicing variant associates to restless legs syndrome

2016

Abstract INTRODUCTION: RLS is a common movement disorders with a strong genetic component in its pathophysiology, but, up to now, no causative mutation has been reported. METHODS: We re-evaluated the previously described RLS2 family by exome sequencing. RESULTS: We identified fifteen variations in the 14q critical region. The c.485G > A transition of the TRAPPC6B gene segregates with the RLS2 haplotype, is absent in 200 local controls and is extremely rare in 12988 exomes from the Exome Variant Server (EVS). This variant alters a splicing site and hampers the normal transcript processing by promoting exon 3-skipping as demonstrated by minigene transfection and by patient transcripts. CON…

0301 basic medicineExome sequencingMaleVesicular Transport ProteinsLocus (genetics)VariationGene mutationBiologySplicingTransfection03 medical and health sciencesExonGene FrequencyRLSRestless Legs SyndromeAnimalsHumansGenetic Predisposition to DiseaseRNA MessengerRestless legs syndromeExomeExome sequencingMovement disorderCells CulturedGeneticsChromosomes Human Pair 14Family HealthSleep disorderHaplotypeExonsRats030104 developmental biologyAuthors report no disclosureNeurologyHaplotypesRNA splicingMutationFemaleNeurology (clinical)Geriatrics and GerontologyNeurological diseaseMinigene
researchProduct

Autism is a prenatal disorder: Evidence from late gestation brain overgrowth

2018

This retrospective study aimed to specify the critical period for atypical brain development in individuals with autism spectrum disorder (ASD) using prenatal and postnatal head growth parameters. The sample consisted of 80 Caucasian, unrelated, idiopathic patients with ASD born after 1995. Fetal ultrasound parameters (head circumference [HC], abdominal circumference, and femur length) were obtained during the second and third trimesters of gestation. HC at birth and postnatal parameters at 12 and 24 months of age were also collected. Head overgrowth, assessed by HC, was highlighted during the second (20-26 weeks of amenorrhea) and third (28-36 weeks of amenorrhea) trimesters. Normal growth…

0301 basic medicineFetusPediatricsmedicine.medical_specialtybusiness.industryGeneral Neurosciencemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineNeurodevelopmental disorderAutism spectrum disorderIn uteromedicineGestationAutismAmenorrheaNeurology (clinical)medicine.symptombusinessPathological030217 neurology & neurosurgeryGenetics (clinical)Autism Research
researchProduct

A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction

2019

Food addiction is linked to obesity and eating disorders and is characterized by a loss of behavioral control and compulsive food intake. Here, using a food addiction mouse model, we report that the lack of cannabinoid type-1 receptor in dorsal telencephalic glutamatergic neurons prevents the development of food addiction-like behavior, which is associated with enhanced synaptic excitatory transmission in the medial prefrontal cortex (mPFC) and in the nucleus accumbens (NAc). In contrast, chemogenetic inhibition of neuronal activity in the mPFC-NAc pathway induces compulsive food seeking. Transcriptomic analysis and genetic manipulation identified that increased dopamine D2 receptor express…

0301 basic medicineFood addictionSciencemedicine.medical_treatmentPrefrontal CortexAddictionGeneral Physics and AstronomyNucleus accumbensNeurotransmissionBiologySynaptic TransmissionNucleus AccumbensArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesGlutamatergic0302 clinical medicineReceptor Cannabinoid CB1Dopamine receptor D2Behavioural genetics ; AddictionNeural Pathwaysmental disordersmedicineAnimalsPremovement neuronal activitylcsh:SciencePrefrontal cortexMice KnockoutMultidisciplinaryReceptors Dopamine D2Gene Expression ProfilingQdigestive oral and skin physiologyFeeding BehaviorGeneral ChemistryUp-RegulationDisease Models Animal030104 developmental biologyGene Expression RegulationBehavioural geneticslcsh:QFood AddictionCannabinoidNeuroscience030217 neurology & neurosurgery
researchProduct

Potential benefits of colostrum in gastrointestinal diseases

2016

This paper reviews the composition of colostrum and the potential preventive and therapeutic use of this "first milk" for treating various gastrointestinal disorders in humans. Colostrum is a complex biological liquid that is richer in antimicrobial peptides, immune-regulating compounds and growth factors than the subsequent mature milk. The main functions of colostrum are to provide essential nutritional components, strengthen the natural defense system, modulate immune response, balance intestinal microbiota and enhance the growth and repair of several tissues. Several studies and clinical trials carried out both in vitro and in vivo on humans and animals suggest the clinical benefits of …

0301 basic medicineGastrointestinal Diseasesanimal diseasesAntimicrobial peptidesPhysiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesImmune systemfluids and secretionsImmunityIn vivogastrointestinal diseases dysbiosis colostrumMedicineAnimalsHumansClinical significanceColostrum Anti-Microbical Factors Immunity Growth Factors Intestinal Disorders ReviewGeneral Immunology and Microbiologybusiness.industryColostrumfood and beveragesmedicine.diseaseClinical trial030104 developmental biologyDietary SupplementsColostrumCattleFemalebusinessDysbiosis
researchProduct

Genetics and Gene Therapy of Anderson-Fabry Disease.

2018

Fabry's disease is a genetic disorder of X-linked inheritance caused by mutations in the alpha galactosidase A gene resulting in deficiency of this lysosomal enzyme. The progressive accumulation of glycosphingolipids, caused by the inadequate enzymatic activity, is responsible of organ dysfunction and thus of clinical manifestations. In the presence of a high clinical suspicion, a careful physical examination and specific laboratory tests are required, finally diagnosis of Fabry's disease is confirmed by the demonstration of absence or reduced alpha-galactosidase A enzyme activity in hemizygous men and gene typing in heterozygous females; in fact the performance of enzymatic activity assay …

0301 basic medicineGenetic enhancementChaperone therapyDisease030204 cardiovascular system & hematologyBioinformaticsMice0302 clinical medicineAlpha galactosidase ADrug DiscoveryGenetics (clinical)KidneybiologyTrihexosylceramidesGenetic disorderEnzyme replacement therapyDependovirusRecombinant ProteinsAlpha galactosidase A; Chaperone therapy; Enzyme replacement therapy; Fabry disease; Gene therapy; Viral vectors; Molecular Medicine; Molecular Biology; Genetics; Drug Discovery3003 Pharmaceutical Science; Genetics (clinical)Isoenzymesmedicine.anatomical_structureMolecular Medicinemedicine.symptomGenetic Vectors03 medical and health sciencesGene therapyViral vectorRare DiseasesGeneticGeneticsmedicineAnimalsHumansEnzyme Replacement TherapyMolecular BiologyAlpha-galactosidasebusiness.industryDrug Discovery3003 Pharmaceutical ScienceOrgan dysfunctionGenetic Therapymedicine.diseaseFabry diseaseDisease Models Animal030104 developmental biologyalpha-GalactosidaseMutationbiology.proteinFabry DiseasebusinessBiomarkersCurrent gene therapy
researchProduct

Treatment strategies for lysosomal storage disorders.

2017

Over the past several years the number of treatments available for patients with lysosomal storage disorders has rapidly increased. Haematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction, and chaperone therapies are currently available, and gene therapies and other treatments are rapidly advancing. Despite remarkable advances, the efficacy of most of these therapies is limited, particularly because the treatments are usually initiated when organ damage has already occurred. To circumvent this limitation, screening in newborn infants for lysosomal storage disorders has been introduced in many countries. However, this screening is complicated by the broad cl…

0301 basic medicineGenetic enhancementLysosomal storage disordersBioinformatics03 medical and health sciences0302 clinical medicineDevelopmental NeuroscienceSlow progressionMedicineHumansEnzyme Replacement Therapybusiness.industryHematopoietic Stem Cell TransplantationEnzyme replacement therapyGenetic TherapyOrgan damageTransplantationLysosomal Storage Diseases030104 developmental biologyPediatrics Perinatology and Child HealthImmunologyTreatment strategyNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryMolecular ChaperonesDevelopmental medicine and child neurology
researchProduct